GlassScriptPhysician profile
Temitope Fowora
NPI 1972998086
$17,219.54
in general payments reported to CMS, 2019-2025
42 companies · $3,270 in 2025
The $3,270 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,142 · 2022: $2,234 · 2023: $3,482 · 2024: $7,093 · 2025: $3,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $2,490 · Travel and Lodging: $756 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,354.10 |
| Consulting Fee | $2,490.00 |
| Travel and Lodging | $756.20 |
| Education | $243.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,142.94 | 2021-2025 | Ofev, Stiolto Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $1,971.15 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,947.79 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $1,601.37 | 2021-2025 | |
| Harmony Biosciences LLC | $846.61 | 2023-2025 | Wakix |
| Axsome Therapeutics, INC. | $728.09 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $650.42 | 2021-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $445.41 | 2021-2025 | Dupixent |
| Amgen INC. | $375.65 | 2021-2025 | Tezspire |
| Grifols USA, LLC | $364.00 | 2022-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $358.13 | 2021-2023 | Yupelri |
| Genzyme Corporation | $347.95 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $334.34 | 2021-2024 | |
| Insmed, INC. | $331.12 | 2021-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $307.93 | 2021-2025 | Acthar |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $296.77 | 2022-2025 | Opsumit, Opsynvi, Uptravi |
| Genentech USA, INC. | $255.61 | 2021-2025 | Xolair |
| Merck Sharp & Dohme LLC | $231.05 | 2022-2025 | Zerbaxa, Belsomra, Keytruda |
| Baxter Healthcare | $224.94 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System, Hillrom - Life 2000 Ventilation System |
| Avadel Cns Pharmaceuticals, LLC | $203.57 | 2023-2025 | Lumryz |
| Vifor Pharma, INC. | $163.83 | 2024-2025 | Zemaira |
| Electromed, INC. | $125.14 | 2021-2025 | Smartvest |
| United Therapeutics Corporation | $118.11 | 2023-2025 | Tyvaso, Tyvaso |
| Paratek Pharmaceuticals, INC. | $104.23 | 2021-2022 | |
| Gilead Sciences, INC. | $97.97 | 2021-2022 | |
| 3b Medical, INC. | $75.11 | 2024-2025 | Luna |
| Philips North America LLC | $59.70 | 2021-2023 | |
| Inogen, INC. | $59.68 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pfizer INC. | $52.82 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $51.57 | 2022 | |
| Viatris Specialty LLC | $48.60 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $43.45 | 2021-2023 | Airduo Digihaler |
| Tactile Systems Technology INC | $42.87 | 2024 | Flexitouch Plus, Entre Plus |
| Verona Pharma, INC. | $34.17 | 2025 | Ohtuvayre |
| Shionogi INC | $25.73 | 2022 | |
| Abbvie INC. | $25.41 | 2022 | |
| Vanda Pharmaceuticals INC. | $24.72 | 2022 | |
| Vapotherm INC | $24.14 | 2022 | |
| Advanced Respiratory, INC | $23.03 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.26 | 2022 | |
| Nabriva Therapeutics, Plc | $17.76 | 2021 | |
| Eisai INC. | $17.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Temitope Fowora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.